2-(4-Chloro-2-fluorophenyl)propan-2-amine | 920501-76-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Chloro-2-fluorophenyl)propan-2-amine
• CAS: 920501-76-4
• 化学式: C₉H₁₁ClFN
• 分子量: 187.64
• InChiKey: JAOVJYBFZGGJEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] DÉRIVÉS DE 1,4-BENZODIAZÉPINONE TRICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II
  申请人：MAVALON THERAPEUTICS LTD

  公开号：WO2017081483A1

  公开（公告）日：2017-05-18

  The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The tricyclic 1,4-benzodiazepinone derivatives of formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides tricyclic 1,4-benzodiazepinone derivatives of formula (I) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mGluRs, and more specifically positive allosteric modulators of mGluR3. (I)

  本发明提供了一类新型的三环1,4-苯并二氮杂卓酮衍生物，其通式为(I)，以及含有这些化合物的药物组合物。此外，通式(I)的化合物及其药物组合物被提供用于治疗和/或预防与谷氨酸能信号传导和/或功能改变相关的病症，以及可以通过改变哺乳动物中谷氨酸水平或信号传导而受影响的病症。通式(I)的三环1,4-苯并二氮杂卓酮衍生物可以作为神经系统中对谷氨酸敏感的受体调节剂，特别是作为代谢型谷氨酸受体(mGluRs)的调节剂，这使得它们特别适合用于治疗和/或预防急性和慢性神经和/或精神障碍。本发明进一步提供通式(I)的三环1,4-苯并二氮杂卓酮衍生物，它们是代谢型谷氨酸受体(mGluRs)的调节剂，特别是mGluRs的正变构调节剂，更具体地说是mGluR3的正变构调节剂。(I)
• Amide Derivatives as Kinase Inhibitors
  申请人：Defert Olivier Raynald

  公开号：US20090118283A1

  公开（公告）日：2009-05-07

  The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar 1 , Ar 2 , R 1 , R 3 , p and n have the meaning defined in the claims In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

  本发明涉及新的AGC激酶抑制剂，特别是公式（I）或（II）的化合物或其立体异构体、互变异构体、外消旋体、代谢物、前药或前药、盐、水合物或溶剂化物，其中Ar1、Ar2、R1、R3、p和n在权利要求中定义。特别地，本发明涉及更具体的AGC激酶抑制剂、包含这种抑制剂的组合物，特别是药物，以及在治疗和预防疾病中使用这种抑制剂的用途。
• Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
  申请人：Domain Therapeutics

  公开号：US11008323B2

  公开（公告）日：2021-05-18

  The present invention provides novel tricyclic 1,4-benzodiazepinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The tricyclic 1,4-benzodiazepinone derivatives of formula (I) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides tricyclic 1,4-benzodiazepinone derivatives of formula (I) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mGluRs, and more specifically positive allosteric modulators of mGluR3.

  本发明提供了通式(I)的新型三环 1,4-苯并二氮杂卓酮衍生物和含有它们的药物组合物。此外，本发明提供的通式（I）化合物和含有它们的药物组合物可用于治疗和/或预防与谷氨酸能信号传导和/或功能改变相关的病症，和/或可受哺乳动物体内谷氨酸水平或信号传导改变影响的病症。式（I）的三环 1,4-苯并二氮杂卓酮衍生物可作为对谷氨酸敏感的神经系统受体的调节剂，特别是作为代谢谷氨酸受体（mGluRs）的调节剂，这使它们特别适用于治疗和/或预防急性和慢性神经和/或精神疾病。本发明进一步提供了式(I)的三环 1,4-苯并二氮杂卓酮衍生物，它们是代谢型谷氨酸受体（mGluRs）的调节剂，特别是 mGluRs 的正性异位调节剂，更具体地说是 mGluR3 的正性异位调节剂。
• SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Mavalon Therapeutics Limited

  公开号：EP3374360A1

  公开（公告）日：2018-09-19
• [EN] AMIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES D'AMIDE UTILISES COMME INHIBITEURS DES KINASES
  申请人：DEVGEN NV

  公开号：WO2007006546A1

  公开（公告）日：2007-01-18

  [EN] The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar¹, Ar², R¹, R³, p and n have the meaning defined in the claims In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.
  [FR] L'invention concerne des inhibiteurs des kinases de la famille AGC, plus précisément des composés de formules (I) ou (II) ou un stéréoisomère, un tautomère, un élément racémique, une métabolite ou un pro ou prémédicament, un sel, un hydrate ou un solvate de ceux-ci, dans lesquelles Ar¹, Ar², R¹, R³, p et n ont la signification définie dans les revendications. Plus précisément, l'invention concerne des inhibiteurs des kinases de la famille AGC, des compositions, notamment des produits pharmaceutiques, comprenant ces inhibiteurs et des utilisations de tels inhibiteurs dans le traitement et la prophylaxie de maladie.